CureFIP™ GS-441524 Injectable 20mg/ml
$80.87
Description
CureFIP™ GS-441524 Injectable 20mg/ml
Precision Dosing Formulation for Small Cats and Kittens
What This Product Is
CureFIP™ GS-441524 20mg/ml is the lowest-concentration injectable in our range. It contains the same active antiviral compound — GS-441524 — as our 30mg/ml and 40mg/ml formulations. The total dose of GS-441524 delivered per treatment (measured in mg per kg of body weight) is identical across all three concentrations. Concentration does not determine efficacy. It determines injection volume — and injection volume determines dosing accuracy.
Why Concentration Matters for Small Cats
FIP treatment dosing is calculated in mg of GS-441524 per kg of body weight. In cats weighing under 2.5 kg, the required dose per injection is small in absolute terms. When that small dose is drawn from a high-concentration formulation, the resulting injection volume becomes extremely small — often below the reliable measurement threshold of standard syringes.
A measurement error of 0.05ml in a 0.1ml injection represents a 50% dosing error. In FIP treatment, consistent and accurate dosing across all 84 days of the protocol directly influences treatment outcome. Underdosing extends the time to remission and increases resistance risk. Overdosing creates unnecessary burden on a small cat’s physiology.
The 20mg/ml format resolves this by producing a clinically manageable injection volume for cats in the under-2.5 kg weight range, where dosing precision matters most.
Indicated Cases
This formulation is appropriate for:
- Adult cats weighing under 2.5 kg
- Kittens diagnosed with FIP at any stage
- Cats that have lost significant weight during illness and now fall below 2.5 kg
- Cases where the attending veterinarian has specified low-concentration formulation for precision dosing
This Formulation Is Not the First Choice For
- Cats weighing 2.5 kg or above — the 30mg/ml formulation is more appropriate
- Cases requiring high-dose induction protocols — the 40mg/ml formulation is indicated
- Cases presenting with anaemia, neurological involvement, or significant appetite loss — consider the CureFIP™ GS-441524 + B12 20mg/ml formulation, which integrates cobalamin support alongside antiviral treatment
Clinical Background
GS-441524 is a nucleoside analogue that functions as an RNA-dependent RNA polymerase (RdRp) inhibitor. Following cellular uptake and phosphorylation to its active triphosphate form, it is incorporated into nascent viral RNA chains, causing delayed chain termination and halting feline coronavirus (FCoV/FIPV) replication. The compound was identified as an effective FIP treatment in landmark research published in Nature in 2019 (Pedersen et al.) and has since been evaluated in multiple prospective and retrospective clinical studies across thousands of cases globally.
The 20mg/ml concentration contains the same pharmaceutical-grade GS-441524 as all CureFIP™ injectable formulations. Concentration variation is a manufacturing and clinical precision decision, not a quality distinction.
Concentration Selection Guide
| Concentration | Primary Indication |
|---|---|
| 20mg/ml (this product) | Cats under 2.5 kg · Kittens · Precision low-volume dosing |
| 30mg/ml | Cats 2.5–5 kg · Standard FIP cases · First-line treatment |
| 40mg/ml | Cats over 5 kg · High-dose protocols · Resistance · Relapse |
| 20mg/ml + B12 | Cats under 2.5 kg with anaemia, neurological symptoms, or appetite loss |
Administration
Administer subcutaneously once daily. Dose is calculated in mg of GS-441524 per kg of body weight. The standard treatment duration is 84 days of consecutive daily dosing without interruption. Do not adjust dose without veterinary guidance. Use the dosing calculator to determine the correct volume for your cat’s current weight.
Treatment response is typically observed within the first 7 days — appetite improvement, reduction in fever, and increased activity are the earliest indicators. If no response is observed within 7 days, contact our clinical support team before discontinuing treatment.
Quality and Sourcing
CureFIP™ injectables are manufactured to pharmaceutical-grade standards with documented API sourcing, concentration verification, and stability testing. Each batch is tested for GS-441524 concentration accuracy before release. We provide full transparency on formulation specifications — contact our team for batch documentation if required for veterinary records.
Specifications
Product Specifications — GS-441524 Injectable Solution
| Parameter | Value |
|---|---|
| Active ingredient | GS-441524 |
| Chemical formula | C₁₂H₁₃N₅O₄ |
| Concentration | 20 mg/ml |
| Volume | 8 ml per vial |
| Purity | ≥ 99.4% |
| pH | 1.9–2.2 |
| Quantity | 1 vial |
Formulation
5% ethanol, 30% propylene glycol, 45% PEG 400, 20% water for injection.
Storage
Store at room temperature (15–25°C / 59–77°F). Do not refrigerate or freeze. Temperatures below 8°C (46°F) may cause the active pharmaceutical ingredient to precipitate or crystallize, compromising the solution's uniformity and dosing accuracy.
Shelf life: 12 months from date of manufacture when stored as directed.
Dosage
Dosage is determined by FIP type and your cat's current body weight. Weigh your cat weekly and recalculate — as your cat recovers and gains weight, the dose must increase accordingly.
| FIP Type | Starting Dose |
|---|---|
| Wet (effusive) | 6 mg/kg |
| Dry (non-effusive) | 8 mg/kg |
| Ocular | 10 mg/kg |
| Neurological | 10 mg/kg |
If no clinical improvement is observed by day 5–7, increase the dose by +2 mg/kg. Do not reduce the dose during treatment, even if symptoms appear to resolve — premature dose reduction increases the risk of relapse.
Treatment Protocol
One subcutaneous injection per day, every day, for a minimum of 84 days (12 weeks). No rest days. Consistency is critical to achieving sustained viral suppression and preventing resistance.
After completing the 84-day course, monitor your cat closely for an additional 84 days. If symptoms recur during the observation period, restart treatment at the previous dose +2 mg/kg.
Clinical Reference
Dosing protocol based on Pedersen et al. (2019), Journal of Feline Medicine and Surgery. Published efficacy data from UC Davis clinical trials. View published study → www.ncbi.nlm.nih.gov/pmc/articles/PMC6435921/
Contact Us
- +973 00000000
- info@curefipv.com
COPYRIGHT © CUREFIPV. ALL RIGHTS RESERVED.
Reviews
There are no reviews yet.